MyMD Pharmaceuticals News

MYMDDelisted Stock  USD 1.82  0.02  1.09%   
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
over three months ago at news.google.com         
TNF Pharmaceuticals Begins Trading Under New Nasdaq Stock Symbol TNFA Effective Before Market Open T...
Google News at Macroaxis
over three months ago at news.google.com         
MyMD Pharmaceuticals is no more Meet TNF Pharmaceuticals - FiercePharma
Google News at Macroaxis
over three months ago at finance.yahoo.com         
MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
Yahoo News
over three months ago at seekingalpha.com         
MyMD Pharma announces rebranding to TNF Pharmaceuticals
seekingalpha News
over three months ago at investorplace.com         
MYMD Stock Earnings MyMD Pharmaceuticals Reported Results for Q1 2024
sbwire news
over three months ago at news.google.com         
MYMD Stock Earnings MyMD Pharmaceuticals Reported Results for Q1 2024 - InvestorPlace
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Insider Trading
Macroaxis News
over six months ago at benzinga.com         
Acquisition by Silverman Joshua of 219000 shares of MyMD Pharmaceuticals subject to Rule 16b-3
benzinga news
over six months ago at news.google.com         
MyMD Pharmaceuticals expands preferred stock By Investing.com - Investing.com
Google News at Macroaxis
over six months ago at businesswire.com         
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitche...
businesswire News
over six months ago at www.macroaxis.com         
Insider Trading
Macroaxis News
over six months ago at news.google.com         
We Think MyMD Pharmaceuticals Can Afford To Drive Business Growth - Yahoo New Zealand News
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 3854626 shares by Pharmacyte Biotech, Inc. of MyMD Pharmaceuticals at 1.816 subject t...
Macroaxis News
over six months ago at businesswire.com         
PharmaCyte Biotech Makes 7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused...
businesswire News
over six months ago at seekingalpha.com         
PharmaCyte Biotech announces 7 million strategic investment in MYMD
seekingalpha News
Far too much social signal, news, headlines, and media speculation about MyMD Pharmaceuticals that are available to investors today. That information is available publicly through MyMD media outlets and privately through word of mouth or via MyMD internal channels. However, regardless of the origin, that massive amount of MyMD data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MyMD Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MyMD Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MyMD Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MyMD Pharmaceuticals alpha.

MyMD Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
PharmaCyte Biotech Makes 7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
05/21/2024
2
Disposition of 3854626 shares by Pharmacyte Biotech, Inc. of MyMD Pharmaceuticals at 1.816 subject to Rule 16b-3
05/23/2024
3
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
06/17/2024
4
MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
07/22/2024
5
TNF Pharmaceuticals Begins Trading Under New Nasdaq Stock Symbol TNFA Effective Before Market Open Today - StockTitan
07/24/2024
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Consideration for investing in MyMD Stock

If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets